SCHEMBL6920773

SCHEMBL6920773

CN1CCc2nc3cc(-c4ccc(F)cc4)ccc3c(=O)n2CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
CYP2C19 P33261 2/20 0.49
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TRPV4 Q9HBA0 2/20 0.41
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
BCHE P06276 1/20 0.41
CFTR P13569 1/20 0.41
ALOX15 P16050 1/20 0.41
ACHE P22303 1/20 0.41
HKDC1 Q2TB90 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GOPC Q9HD26 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921266 0.93 RAB9A (0.50) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL6921264 0.93 LMNA (0.53) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL12058968 0.90 LMNA (0.47) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL6923306 0.89 RAB9A (0.43) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL12059389 0.86 RAB9A (0.45) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL6920979 0.85 RAB9A (0.45) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL9994599 0.85 LMNA (0.47) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL6922253 0.84 RAB9A (0.63) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL6920781 0.83 LMNA (0.48) LMNACYP2C19RAB9ANPC1ALDH1A1
SCHEMBL12059068 0.83 LMNA (0.50) LMNACYP2C19RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 LMNA 4613/4885CYP2C19 4711/4885RAB9A 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.